Spectroscopy Can Accurately Diagnose Breast Lesions

This article originally appeared here.
Share this content:
Spectroscopy Technique Accurate in Breast Lesion Diagnosis
Spectroscopy Technique Accurate in Breast Lesion Diagnosis

(HealthDay News) -- A Raman spectroscopy technique can very accurately diagnose breast lesions and detect microcalcifications in core needle biopsies, according to a study published in the June 1 issue of Cancer Research.

Ishan Barman, Ph.D., from the Massachusetts Institute of Technology in Cambridge, and colleagues obtained Raman spectra from fresh stereotactic core needle biopsies from 33 women at 50 normal tissue sites, 77 lesions with microcalcifications, and 19 lesions without microcalcifications. The data were used to develop a single-step diagnostic algorithm to distinguish normal from abnormal tissue in the absence and presence of microcalcifications.

The researchers found that the algorithm had a sensitivity of 62.5 percent, a specificity of 100 percent, a positive predictive value of 100 percent, and a negative predictive value of 95.6 percent for the diagnosis of breast cancer with or without microcalcifications. The algorithm could classify normal tissue, fibrocystic change, fibroadenoma, or breast cancer, with or without microcalcifications, with an overall accuracy of 82.2 percent. The authors note that ductal carcinoma in situ (DCIS) was the most commonly diagnosed breast cancer and are the most common lesion associated with microcalcifications.

"Our study shows the potential of Raman spectroscopy to concomitantly detect microcalcifications and diagnose associated lesions, including DCIS, and thus provide real-time feedback to radiologists during such biopsy procedures, reducing nondiagnostic and false-negative biopsies," Barman and colleagues conclude.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs